A new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.